PTC Therapeutics (FRA:BH3) Short Interest


FRA:BH3 PTC Therapeutics Inc FRA:BH3
51 GF Score
Price €72.26
GF Value €30.17
! 9 Warning Signs
View Full Analysis

What is PTC Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:BH3 vs APGE, MIRM, RYTM: Short Interest Comparison

For the Biotechnology subindustry, PTC Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PTC Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's Short Interest falls into.


FRA:BH3
51GF Score
PTC Therapeutics Inc FRA:BH3
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PTC Therapeutics (FRA:BH3) Overvalued in 2026?

Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued. The current stock price of €72.26 is trading 139.5% above its estimated GF Value™ of €30.17.

Key valuation signals for FRA:BH3:

  • Short Interest:
  • GF Value™: €30.17 vs. price of €72.26 (139.5% above fair value)
  • GF Score™: 51/100 with 9 warning signs

No single metric tells the full story. See the FRA:BH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PTC Therapeutics Business Description

Other Exchanges PTCT:USABH3:Germany
Address 500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
51GF Score

Get the complete analysis for FRA:BH3

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€72.26
Price
€30.17
GF Value